Polycyclic tetramate macrolactam (PTM) natural products are produced by actinomycetes and 9 other bacteria. PTMs are often bioactive, and the simplicity of their biosynthetic clusters make 10 them attractive for bioengineering. Clifednamide-type PTMs from Streptomyces sp. JV178 contain 11 a distinctive ketone group, suggesting the existence of a novel PTM oxidizing enzyme. Here, we 12 report the new cytochrome P450 enzyme (CftA) is required for clifednamide production. Genome 13 mining was used to identify several new clifednamide producers, some having improved 14 clifednamide yields. Using a parallel synthetic biology approach, CftA isozymes were used to 15 engineer the ikarugamycin pathway of Streptomyces sp. NRRL F-2890 to yield clifednamides. 16 Further, we observed that strong CftA expression leads to the production of a new PTM, 17 clifednamide C. We demonstrate the utility of both genome mining and synthetic biology to rapidly 18 increase clifednamide production and identify a PTM tailoring enzyme for rational molecule 19 design. 20 21 2 KEYWORDS 22
5-gene PTM locus that likely encodes the clifednamides. Homology analysis of these genes 48 allowed us to propose a plausible clifednamide biosynthetic pathway ( Figure S1 ). 49 Three of the genes, ikaA, ikaB and ikaC, recapitulate the ikarugamycin cluster 12 . As such, Figure S1 ) 18 . 54 The resulting tetramate-polyene product is reductively cyclized by IkaB and IkaC to produce the 55 5-6-5 carbon ring system shared by ikarugamycin and clifednamides 19 . A ftdA homolog was also 56 found in the cluster. A PTM hydroxylase common to a number of PTM pathways 7,20,21 , ftdA is 57 likely responsible for the C25 hydroxyl group of clifednamide B. The remaining open reading 58 frame is encoded between ikaA and ikaB ( Figure 1A ). Predicted to encode a novel cytochrome 59 P450, we reasoned its cognate enzyme (designated CftA, for clifednamide tailoring A) may install 60 the C29 ketone of the clifednamides. No additional PTM genes were detected in the JV178 61 genome, further suggesting the cftA-containing cluster encodes the clifednamides.
62
JV178 was found to be a poor host for genetic analysis (unpublished), preventing experimental 63 verification of the above model. To further study clifednamide biosynthesis, a genome mining 64 approach was used to identify additional producers. Several actinomycetes having publicly 65 4 available genome sequences were found to harbor PTM clusters syntenic with the JV178 locus 66 ( Figure S2 ). Four such strains were obtained from the USDA NRRL strain collection. Each strain 67 was grown on a panel of solid media and extracted with ethyl acetate for LC-MS/MS analysis.
68
Clifednamide production was determined by comparison with extracts containing clifednamides 69 A and B from JV178. All four strains appear to produce both compounds based on product 70 retention times, UV absorbance spectra, and mass fragmentation patterns ( Figure 2 ). Notably, S. 71 negayawaensis produced approximately 26 μM of clifednamides A and B combined, about 10-72 fold greater than JV178 ( Figure 2E , Table 1 ). The other three strains, S. purpeofuscus, S. sp. F-73 6131, and S. torulosus produced considerably lower amounts ( Figure 2B -D). Interestingly, a local 74 PTM-producing soil isolate (Streptomyces sp. KL33) also produced clifednamide A titers 75 comparable to S. negayawaensis, but no clifednamide B was detected ( Figure 2F ).
76
Of the newly obtained clifednamide producers, Streptomyces. sp. NRRL F-6131 proved to be the 77 most amenable to intergeneric conjugation. This strain was thus used to interrogate clifednamide 78 biosynthesis. A rpsL(K43N) mutant was isolated for streptomycin counterselection 22 . As noted for 79 other Streptomyces metabolites, this lesion also increased PTM production 23 ( Figure 3A&B ).
80
Markerless cftA deletion resulted in the loss of clifednamide production. However, the strain 81 produced increased amounts of a previously minor compound (m/z 479) ( Figure 3C ). This peak 82 was confirmed to be ikarugamycin by comparison with an authentic standard, and its apparent 83 accumulation is consistent with it being a clifednamide biosynthetic precursor. An additional peak 84 of interest (m/z 495) was detected in the ΔcftA mutant. This was tentatively identified as Table   104 1). No clifednamide B or butremycin was observed in any of these strains due to ftdA being absent 105 in the host. In general, constructs driven by the stronger pHM11a 28 -derived promoter converted 106 more ikarugamycin precursor to clifednamide A than the pDA1652-derived promoter 29 .
107
Additionally, all four pHM11a constructs and two pDA1652 constructs resulted in a new peak labeling with 2 H7-L-ornithine results in a correspondingly heavier mass (m/z 516) and daughter 112 ion (m/z 146). These results parallel our results from clifednamide A ( Figure S5 ). Based on these 113 results, we designated this peak clifednamide C. Its mass difference (m/z +30) from ikarugamycin 114 (m/z 479) and shorter C18 retention time suggest it has been oxidized twice. The first oxidation 115 presumably corresponds to the C29 keto oxidation by CftA to produce clifednamide A (m/z 493).
116
The subsequent oxidation of clifednamide A to clifednamide C is consistent with a hydroxylation 117 (m/z +16), perhaps resulting from above-optimal CftA activity. A clifednamide C peak was also 118 detected in S. negayawaensis, confirming its production in un-engineered clifednamide producers.
119
The tandem oxidation of clifednamide A by CftA is analogous to the activity of the recently 120 characterized IkaD 30 . A cytochrome P450 associated with some ikarugamycin biosynthetic 121 clusters, IkaD primarily installs an epoxide across carbons 7 and 8. However, it can also 122 hydroxylate C29, the same position targeted for keto insertion by CftA ( Figure S1 ). We noted that 123 Streptomyces sp. NRRL F-2890, the ikarugamycin-producing host strain, also contains an IkaD 124 homolog. While F-2890 produces a small peak that is consistent with the mass of ikarugamycin 
138
In conclusion, we used a combination of comparative genomics, genetics, and genome mining to 139 reveal the novel cytochrome P450 CftA is responsible for clifednamide production. We engaged 140 in a synthetic biological approach to engineer clifednamide production by utilizing cftA orthologs 141 sourced from newly identified clifednamide producing strains. In addition to increased 142 clifednamide production over Streptomyces sp. JV178, we noted substantial differences from cftA 143 homologs. As such, this work demonstrates the value of leveraging genome-mined panels of 144 isozymes in a plug-and-play fashion to rapidly identify efficient biocatalysts. Further, we show 145 CftA belongs to an expanding family of PTM cytochrome P450 enzymes with the apparent 146 capability to carry out multiple oxidation events. These enzymes may be useful to engineer 147 diversity-oriented panels of PTMs for future bioactivity and structure-function analyses. 
